87272-20-6

MEDICA 16 is a β,β''-dimethyl hexadecanedioic acid which exhibits hypolipidemic and antidiabetogenic effects in the rat. In animals that were fed a diet which was 0.25% MEDICA 16 by weight, the hypolipidemic effect consisted of a 70-80% decrease in plasma chylomicrons and VLDL-triacylglycerols as well as a 40-60% decrease in plasma VLDL-cholestrol.

MEDICA 16 is a β,β'-dimethyl hexadecanedioic acid which exhibits hypolipidemic and antidiabetogenic effects in the rat. In animals that were fed a diet which was 0.25% MEDICA 16 by weight, the hypolipidemic effect consisted of a 70-80% decrease in plasma chylomicrons and VLDL-triacylglycerols as well as a 40-60% decrease in plasma VLDL-cholestrol.

ChEBI: MEDICA 16 is an alpha,omega-dicarboxylic acid that is hexadecanedioic acid carrying methyl groups at positions 3 and 14. It is a free fatty acid 1 (FFA1/GPR40) receptor agonist and an ATP citrate lyase inhibitor, and exhibits hypolipidemic and antidiabetogenic properties. It has a role as an antilipemic drug, an EC 6.4.1.2 (acetyl-CoA carboxylase) inhibitor, an EC 2.3.3.8 (ATP citrate synthase) inhibitor, a G-protein-coupled receptor agonist and a hypoglycemic agent.

Store at -20°C

[1] TAKAFUMI HARA. Novel selective ligands for free fatty acid receptors GPR120 and GPR40.[J]. Naunyn-Schmiedeberg’s archives of pharmacology, 2009, 380 3: 247-255. DOI: 10.1007/s00210-009-0425-9
[2] TIMOTHY N. C. WELLS  Barbara A S. Redox control of catalysis in ATP-citrate lyase from rat liver[J]. The FEBS journal, 1992, 204 1: 249-255. DOI: 10.1111/j.1432-1033.1992.tb16631.x
[3] L. L. ATKINSON. MEDICA 16 inhibits hepatic acetyl-CoA carboxylase and reduces plasma triacylglycerol levels in insulin-resistant JCR: LA-cp rats.[J]. Diabetes, 2002, 51 5 1: 1548-1555. DOI: 10.2337/diabetes.51.5.1548
[4] J C RUSSELL. Development of insulin resistance in the JCR:LA-cp rat: role of triacylglycerols and effects of MEDICA 16.[J]. Diabetes, 1998, 47 5: 770-778. DOI: 10.2337/diabetes.47.5.770